Zealand Pharma A/S (ZEAL) News

Zealand Pharma A/S (ZEAL): $32.45

0.40 (+1.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ZEAL News Items

ZEAL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ZEAL News Highlights

  • ZEAL's 30 day story count now stands at 4.
  • Over the past 24 days, the trend for ZEAL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • DEN, MA and MG are the most mentioned tickers in articles about ZEAL.

Latest ZEAL News From Around the Web

Below are the latest news stories about Zealand Pharma A that investors may wish to consider to help them evaluate ZEAL as an investment opportunity.

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 26/ 2021 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, DK and Boston, MA, U.S., May 3, 2021 – Zealand Pharma A/S (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached files. # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company ...

Yahoo | May 3, 2021

Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes

Company announcement – No. 25 / 2021 Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes Copenhagen, DK and Boston, MA, U.S., May 3, 2021 – Zealand Pharma A/S (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that Diabetes Care has published results from its Phase 3 trial evaluating dasiglucagon for the treatment of severe hypoglycemia in adults with diabetes. The article is available online, and will appear in Diabetes Care. The study found that dasiglucagon administration resulted in a reversal of hypoglycemia (with a median recovery time of 10 mi...

Yahoo | May 3, 2021

With a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors?

A new, easier-to-administer treatment for severe hypoglycemia has observers and investors wondering where its creators will go next.

Yahoo | April 12, 2021

Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

Company announcement – No. 19/ 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, DK and Boston, MA, April 9, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 21,650 divided into 21,650 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma-share at a p...

Yahoo | April 9, 2021

Zealand Pharma to participate in upcoming investor conferences

Company announcement – No. 17 / 2021Zealand Pharma to participate in upcoming investor conferencesCopenhagen, DK and Boston, MA, U.S. March 25, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in April:Guggenheim Virtual Healthcare Talks - Genomic Medicines & Rare DiseaseDate: Thursday, April 1, 2021 20th Annual Virtual Needham Healthcare Conference Date: Monday, April 12, 2021 Presentation: 11:45 a.m. ET/ 4:45 p.m. CETA live webcast of the Needham event will be available on the "Events & Presentations" page in the Inves...

Yahoo | March 25, 2021

Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes

Company announcement – No. 16 / 2021 Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes Zegalogue will be available in both an auto injector and a prefilled syringe for the treatment of severe hypoglycemia in patients with diabetes age 6 or olderApproval based on results from three pivotal trials in adults and children with diabetes, showing median time to blood glucose recovery from severe hypoglycemia of 10 minutes following injection of 0.6 mg/0.6 mL ZegalogueCompany to host conference call Tuesday, March 23 at 1:00PM CET (8:00AM ET) Copenhagen, DK and Boston, MA, U.S. March 22, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company aspiring to deliver innovation ...

Yahoo | March 22, 2021

Zealand Pharma A/S (NASDAQ:ZEAL) Releases Earnings Results, Misses Estimates By $3.86 EPS

Zealand Pharma A/S (NASDAQ:ZEAL) released its quarterly earnings results on Wednesday. The company reported ($9.76) EPS for the quarter, missing analysts’ consensus estimates of ($5.90) by ($3.86), Fidelity Earnings reports. Zealand Pharma A/S had a negative net margin of 214.31% and a negative return on equity of 38.34%. Shares of Zealand Pharma A/S stock traded […]

Transcript Daily | March 12, 2021

Zealand Pharma A/S (NASDAQ:ZEAL) Issues Quarterly Earnings Results, Misses Expectations By $3.86 EPS

Zealand Pharma A/S (NASDAQ:ZEAL) released its earnings results on Wednesday. The company reported ($9.76) EPS for the quarter, missing the consensus estimate of ($5.90) by ($3.86), Fidelity Earnings reports. Zealand Pharma A/S had a negative return on equity of 38.34% and a negative net margin of 214.31%. Shares of NASDAQ ZEAL traded down $1.67 during […]

Transcript Daily | March 12, 2021

Total number of shares and voting rights in Zealand Pharma at February 28, 2021

Company announcement – No. 11/ 2021 Total number of shares and voting rights in Zealand Pharma at February 28, 2021 Copenhagen, March 9, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. In Company announcement No. 4/2021 from February 1, 2021, Zealand announced an increase in share capital relating to the exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voti...

Yahoo | March 9, 2021

Zealand Pharma A/S (ZEAL) Set to Announce Quarterly Earnings on Thursday

Zealand Pharma A/S (NASDAQ:ZEAL) is set to issue its quarterly earnings data before the market opens on Thursday, March 11th. Analysts expect the company to announce earnings of ($0.98) per share for the quarter. Shares of ZEAL opened at $32.06 on Thursday. Zealand Pharma A/S has a twelve month low of $22.00 and a twelve […]

Transcript Daily | March 4, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5876 seconds.